Development and Validation of a Next-Generation Sequencing–Based Multigene Assay to Predict the Prognosis of Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Han‐Byoel Lee, Sae Byul Lee, Minsu Kim, Sunyoung Kwon, Jeonghee Jo, Jinkyoung Kim, Hee Jin Lee, Han-Suk Ryu, Jong Won Lee, Chungyeul Kim, Jae‐Hwan Jeong, Hyoki Kim, Dong‐Young Noh, In-Ae Park, Sei-Hyun Ahn, Sun Kim, Sungroh Yoon, Aeree Kim, Wonshik HanClinical 2020 · DOI

Abstract

The newly developed and validated NGS-based multigene assay can predict the distant recurrence risk in ER-positive, HER2-negative breast cancer.
BibTeX
@inproceedings{lee2020development,
  author = {Han‐Byoel Lee and Sae Byul Lee and Minsu Kim and Sunyoung Kwon and Jeonghee Jo and Jinkyoung Kim and Hee Jin Lee and Han-Suk Ryu and Jong Won Lee and Chungyeul Kim and Jae‐Hwan Jeong and Hyoki Kim and Dong‐Young Noh and In-Ae Park and Sei-Hyun Ahn and Sun Kim and Sungroh Yoon and Aeree Kim and Wonshik Han},
  title = {{Development and Validation of a Next-Generation Sequencing–Based Multigene Assay to Predict the Prognosis of Estrogen Receptor–Positive, HER2-Negative Breast Cancer}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.1158/1078-0432.ccr-20-2107},
}

Loading related content...

Figure